OBJECTIVE: To investigate the changes of dynamic contrast-enhanced MR imaging (DCE-MRI) parameters at 3 T in cervical cancer patients before and after concurrent chemoradiotherapy (CCRT), and to correlate the parameters with final tumour response to therapy. METHODS: Thirty-five patients with cervical cancer underwent DCE-MRI before CCRT, 4 weeks after starting therapy and at 1 month after the end of therapy. DCE-MRI parameters were calculated in the tumour and normal gluteus muscle. Final response to treatment as determined by changes in tumour size and volume was correlated with pre-treatment DCE-MRI parameters. RESULTS: DCE-MRI parameters (i.e. K (trans), v (e) and k (ep)) in the tumours showed significant changes in response to CCRT (P < 0.05) and in particular K (trans) and v (e) demonstrated early significant increase (P < 0.01), but those in normal muscle did not show a significant difference (P > 0.05). Before therapy, the mean values of K (trans), k (ep), v (e) and v (p) in the tumours were significantly greater than those in muscle (P < 0.05). DCE-MRI parameters of the tumours at pre-treatment were not statistically associated with final tumour size or volume change. CONCLUSION: DCE-MRI parameters may help evaluate early changes of cervical cancer to CCRT, but larger, more definitive studies are needed. KEY POINTS : • DCE-MRI offers new insights into tumour behaviour. • Changes in tumour size lag behind biomarkers which improve quickly in responders. • DCE-MRI is a non-invasive imaging technique that can characterize tumour vasculature. • DCE-MRI of cervical cancer may be useful in monitoring changes with therapy.
OBJECTIVE: To investigate the changes of dynamic contrast-enhanced MR imaging (DCE-MRI) parameters at 3 T in cervical cancerpatients before and after concurrent chemoradiotherapy (CCRT), and to correlate the parameters with final tumour response to therapy. METHODS: Thirty-five patients with cervical cancer underwent DCE-MRI before CCRT, 4 weeks after starting therapy and at 1 month after the end of therapy. DCE-MRI parameters were calculated in the tumour and normal gluteus muscle. Final response to treatment as determined by changes in tumour size and volume was correlated with pre-treatment DCE-MRI parameters. RESULTS:DCE-MRI parameters (i.e. K (trans), v (e) and k (ep)) in the tumours showed significant changes in response to CCRT (P < 0.05) and in particular K (trans) and v (e) demonstrated early significant increase (P < 0.01), but those in normal muscle did not show a significant difference (P > 0.05). Before therapy, the mean values of K (trans), k (ep), v (e) and v (p) in the tumours were significantly greater than those in muscle (P < 0.05). DCE-MRI parameters of the tumours at pre-treatment were not statistically associated with final tumour size or volume change. CONCLUSION:DCE-MRI parameters may help evaluate early changes of cervical cancer to CCRT, but larger, more definitive studies are needed. KEY POINTS : • DCE-MRI offers new insights into tumour behaviour. • Changes in tumour size lag behind biomarkers which improve quickly in responders. • DCE-MRI is a non-invasive imaging technique that can characterize tumour vasculature. • DCE-MRI of cervical cancer may be useful in monitoring changes with therapy.
Authors: H C Wagenaar; J B Trimbos; S Postema; A Anastasopoulou; R J van der Geest; J H Reiber; G G Kenter; A A Peters; P M Pattynama Journal: Gynecol Oncol Date: 2001-09 Impact factor: 5.482
Authors: Juliette A Loncaster; Bernadette M Carrington; Johnathan R Sykes; Andrew P Jones; Susan M Todd; Rachel Cooper; David L Buckley; Susan E Davidson; John P Logue; Robin D Hunter; Catharine M L West Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-01 Impact factor: 7.038
Authors: N A Mayr; W T Yuh; V A Magnotta; J C Ehrhardt; J A Wheeler; J I Sorosky; C S Davis; B C Wen; D D Martin; R E Pelsang; R E Buller; L W Oberley; D E Mellenberg; D H Hussey Journal: Int J Radiat Oncol Biol Phys Date: 1996-10-01 Impact factor: 7.038
Authors: H Hawighorst; P G Knapstein; M V Knopp; W Weikel; G Brix; I Zuna; S O Schönberg; M Essig; P Vaupel; G van Kaick Journal: Cancer Res Date: 1998-08-15 Impact factor: 12.701
Authors: Mark A Zahra; Li Tee Tan; Andrew N Priest; Martin J Graves; Mark Arends; Robin A F Crawford; James D Brenton; David J Lomas; Evis Sala Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-18 Impact factor: 7.038
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: M O Leach; K M Brindle; J L Evelhoch; J R Griffiths; M R Horsman; A Jackson; G C Jayson; I R Judson; M V Knopp; R J Maxwell; D McIntyre; A R Padhani; P Price; R Rathbone; G J Rustin; P S Tofts; G M Tozer; W Vennart; J C Waterton; S R Williams; P Workman Journal: Br J Cancer Date: 2005-05-09 Impact factor: 7.640
Authors: Rasha Elmghirbi; Tavarekere N Nagaraja; Stephen L Brown; Swayamprava Panda; Madhava P Aryal; Kelly A Keenan; Hassan Bagher-Ebadian; Glauber Cabral; James R Ewing Journal: Radiat Res Date: 2016-12-21 Impact factor: 2.841
Authors: Chong Duan; Jesper F Kallehauge; G Larry Bretthorst; Kari Tanderup; Joseph J H Ackerman; Joel R Garbow Journal: Magn Reson Med Date: 2016-03-04 Impact factor: 4.668
Authors: Esme J Hill; Corran Roberts; Jamie M Franklin; Monica Enescu; Nicholas West; Thomas P MacGregor; Kwun-Ye Chu; Lucy Boyle; Claire Blesing; Lai-Mun Wang; Somnath Mukherjee; Ewan M Anderson; Gina Brown; Susan Dutton; Sharon B Love; Julia A Schnabel; Phil Quirke; Ruth Muschel; William G McKenna; Michael Partridge; Ricky A Sharma Journal: Clin Cancer Res Date: 2016-02-09 Impact factor: 12.531